Horvath L, Hellmich B
Vaskulitiszentrum Süd, Klinik für Innere Medizin, Rheumatologie und Immunologie, Medius-Kliniken - Akademisches Lehrkrankenhaus, Universität Tübingen, Eugenstr. 3, 73230, Kirchheim u. Teck, Deutschland.
Z Rheumatol. 2020 Mar;79(2):175-185. doi: 10.1007/s00393-020-00754-x.
Patients with untreated active giant cell arteritis (GCA) are at high risk of permanent vision loss. Therefore, treatment with glucocorticoids should be immediately initiated at an initial dose of 40-60 mg prednisolone equivalent dose per day. Once remission is achieved, the prednisolone dose should be reduced to 15-20 mg within 2-3 months and then to ≤5 mg per day within 1 year. Glucocorticoid-sparing treatment with tocilizumab or alternatively methotrexate should be initiated in patients with an increased risk or pre-existing complications of glucocorticoid treatment and patients with relapse. In polymyalgia rheumatica, prednisolone dosages of 15-25 mg/day are sufficient. After achieving remission, the dose should then be reduced to 10 mg within 4-8 weeks and then to 1 mg per month thereafter. Glucocorticoid-sparing treatment with methotrexate should be initiated in patients with an increased risk or existing complications of glucocorticoid treatment, relapse or increased glucocorticoid requirements.
未经治疗的活动性巨细胞动脉炎(GCA)患者面临永久性视力丧失的高风险。因此,应立即开始使用糖皮质激素治疗,初始剂量为每天40 - 60毫克泼尼松等效剂量。一旦病情缓解,泼尼松剂量应在2 - 3个月内减至15 - 20毫克,然后在1年内减至每天≤5毫克。对于糖皮质激素治疗风险增加或已有并发症的患者以及复发患者,应开始使用托珠单抗或甲氨蝶呤进行糖皮质激素节省治疗。在风湿性多肌痛中,每天15 - 25毫克的泼尼松剂量就足够了。病情缓解后,剂量应在4 - 8周内减至10毫克,然后此后每月减至1毫克。对于糖皮质激素治疗风险增加或已有并发症、复发或糖皮质激素需求增加的患者,应开始使用甲氨蝶呤进行糖皮质激素节省治疗。